Biora Therapeutics Inc (BIOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biora Therapeutics Inc (BIOR) has a cash flow conversion efficiency ratio of 0.082x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.73 Million) by net assets ($-106.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biora Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2023)
This chart illustrates how Biora Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Biora Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
Biora Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biora Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
N/A |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
-0.030x |
|
Sarawak Cable Bhd
KLSE:5170
|
0.002x |
|
Tower Investments SA
WAR:TOW
|
-0.116x |
|
Wingara AG Ltd
AU:WNR
|
-1.348x |
|
Ampli SA w upadlosci ukladowej
WAR:APL
|
0.049x |
|
Aranjin Resources Ltd
V:ARJN
|
-0.499x |
|
1Spatial PLC
LSE:SPA
|
0.062x |
Annual Cash Flow Conversion Efficiency for Biora Therapeutics Inc (2018–2023)
The table below shows the annual cash flow conversion efficiency of Biora Therapeutics Inc from 2018 to 2023. For the full company profile with market capitalisation and key ratios, see Biora Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-101.42 Million | $-48.50 Million | 0.478x | -24.07% |
| 2022-12-31 | $-102.29 Million | $-64.42 Million | 0.630x | -68.05% |
| 2021-12-31 | $-84.98 Million | $-167.49 Million | 1.971x | +27.23% |
| 2020-12-31 | $-106.99 Million | $-165.74 Million | 1.549x | +22.43% |
| 2019-12-31 | $-83.87 Million | $-106.12 Million | 1.265x | -28.18% |
| 2018-12-31 | $-36.97 Million | $-65.13 Million | 1.762x | -- |
About Biora Therapeutics Inc
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more